Jazz Pharmaceuticals (NASDAQ:JAZZ) Posts Earnings Results, Misses Expectations By $0.13 EPS

Jazz Pharmaceuticals (NASDAQ:JAZZ) issued its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported $5.70 earnings per share (EPS) for the quarter, missing the consensus estimate of $5.83 by ($0.13), Zacks reports. Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. Jazz Pharmaceuticals updated its FY 2025 guidance to 22.500-24.000 EPS and its FY 2025 guidance to 22.500-24.000 EPS.

Jazz Pharmaceuticals Stock Performance

Jazz Pharmaceuticals stock traded up $2.98 during mid-day trading on Tuesday, hitting $139.67. 1,271,031 shares of the company’s stock traded hands, compared to its average volume of 640,889. The firm has a 50 day simple moving average of $125.08 and a two-hundred day simple moving average of $118.24. The company has a debt-to-equity ratio of 1.46, a current ratio of 4.26 and a quick ratio of 3.74. The stock has a market cap of $8.44 billion, a price-to-earnings ratio of 19.67, a P/E/G ratio of 1.04 and a beta of 0.56. Jazz Pharmaceuticals has a fifty-two week low of $99.06 and a fifty-two week high of $140.52.

Wall Street Analyst Weigh In

Several analysts have recently commented on JAZZ shares. Wells Fargo & Company raised shares of Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price objective for the stock from $140.00 to $175.00 in a research report on Thursday, December 12th. Royal Bank of Canada restated an “outperform” rating and set a $179.00 target price on shares of Jazz Pharmaceuticals in a research report on Tuesday, December 10th. TD Cowen reduced their target price on shares of Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating on the stock in a research note on Thursday, November 7th. Finally, Needham & Company LLC reissued a “buy” rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a research note on Thursday, December 12th. One research analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $180.33.

Insider Activity at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 2,000 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $121.17, for a total transaction of $242,340.00. Following the completion of the sale, the chief executive officer now directly owns 427,025 shares of the company’s stock, valued at approximately $51,742,619.25. This trade represents a 0.47 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. In the last 90 days, insiders have sold 5,053 shares of company stock worth $617,442. Insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.